Navigation Links
Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
Date:5/7/2013

SAN DIEGO, May 7, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas on Tuesday, May 14, 2013 at 1:40 p.m. PT/4:40 p.m. ET. Kurt Gustafson , Chief Financial Officer, Halozyme Therapeutics, will provide a corporate overview.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA.  For more information on how we are innovating, please visit our corporate website at www.halozyme
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Halozyme Therapeutics Names Matt Posard to Board of Directors
2. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
3. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
4. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
5. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
6. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
7. Halozyme to Host Third Quarter Financial Results Conference Call
8. Halozyme Reports Second Quarter 2012 Financial Results
9. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
10. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
11. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced that the ... Chicago -based Rush University Medical Center in ... escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in ... cervical spinal cord injury (SCI). This represents the ...
(Date:8/31/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... biopharmaceutical company focused on developing and commercializing novel ...
(Date:8/28/2015)... , Aug. 28, 2015  With the heroin ... reaching deadlier heights, Jacksonville -based Lakeview ... Hemphill is helping to explain why fentanyl is ... approximately 40 to 50 times more potent than pharmaceutical ... users as heroin, the risk of death skyrockets. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2
... (OTCQX: DATA), a technology and services company focused on global ... its Vice President of Research and Development, Chris Wilke, has ... 2009 Society for Clinical Data Management (SCDM) Annual Conference which ... Mr. Wilke will be discussing Is 100% EDC Realistic? ...
... ThermalTherapeutic Systems, Inc., developers of a highly ... today the completion of $2.75 Million Series A ... funding by the Pittsburgh Life Sciences Greenhouse, and ... investments by the Pittsburgh Life Sciences Greenhouse and ...
Cached Medicine Technology:DATATRAK to Present at 2009 SCDM Annual Conference 2DATATRAK to Present at 2009 SCDM Annual Conference 3ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures 2
(Date:8/31/2015)... , ... August 31, 2015 , ... Patients who thought ... those who are interested in learning more about the procedure beyond the information found ... , Internationally recognized hair transplant surgeon Parsa Mohebi will be on hand to answer ...
(Date:8/31/2015)... ... 31, 2015 , ... The Bay Pines VA Healthcare System (VAHCS) ... by hiring more doctors and nurses and expanding existing facilities and services. Spine ... July, Dr. Anthony Jabre was selected to lead and grow the Bay Pines VAHCS’s ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... In an ... from the Plastic and Reconstructive Surgery Global Open Journal that discusses the future of ... article discussed how, in the future, customized implants, prosthetics, and other 3-D printed tools ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... State Urology was formed in 2008, the result of a merger of five ... that by working cooperatively, they could provide more cost-effective and higher quality care ...
(Date:8/31/2015)... ... 2015 , ... Since 1946, the doctors and staff at Clifton Dental Associates ... patient arrives at the office, the staff will make them feel welcome and comfortable. ... to create a complete dental treatment plan that is unique to each smile! ...
Breaking Medicine News(10 mins):Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 3Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2
... the U.S. Consume Too Little Choline, PARK RIDGE, Ill., ... such as eggs, is associated with a 24 percent,reduced risk ... grant,from the U.S. National Institutes of Health (NIH), to be ... adds to the growing body,of evidence that links egg consumption ...
... 1 clinical trial to test a novel HIV/AIDS vaccine has ... aims to overcome the problem of preexisting immunity to common ... in the developing world. , This study will ... three immunizations and who will be followed to assess the ...
... 2, 2008 Although sexual dysfunction in some men ... been examined in women. In an article published in ... Medicine, researchers found no increased prevalence or incidence of ... were dissatisfied with their sexual activity. , Researchers from ...
... INSPIRIS CarePlus Nurse Practitioner-Led Care program with Mercy ... Silver Award in the Health Care,Management category in ... empower, protect consumers, WASHINGTON, April 3, 2008 ... Practices in Consumer Empowerment and,Protection Awards competition recently, ...
... Minn., April 3, 2008 The National Committee ... Blue Shield of,Minnesota with a Quality Plus Distinction ... plans that are market leaders for,measuring the quality ... hospitals and,clinics. NCQA is an independent, nonprofit organization ...
... Sales-Leading Detrol LA/Detrusitol XL, According to a New Report ... ... 3, 2008 Decision Resources, one,of the world,s leading research and ... effect on the,reduction of urge urinary incontinence episodes (and the resulting,improvement ...
Cached Medicine News:Health News:Essential Nutrient Found in Eggs Reduces Risk of Breast Cancer by 24 Percent 2Health News:Essential Nutrient Found in Eggs Reduces Risk of Breast Cancer by 24 Percent 3Health News:Essential Nutrient Found in Eggs Reduces Risk of Breast Cancer by 24 Percent 4Health News:Essential Nutrient Found in Eggs Reduces Risk of Breast Cancer by 24 Percent 5Health News:Clinical trial will test new HIV/AIDS vaccine 2Health News:Sexual dissatisfaction in postmenopausal women not linked to cardiovascular disease 2Health News:INSPIRIS and Mercy Care of Arizona Named Winners in URAC's Best Practices in Consumer Empowerment and Protection Awards 2Health News:INSPIRIS and Mercy Care of Arizona Named Winners in URAC's Best Practices in Consumer Empowerment and Protection Awards 3Health News:NCQA Awards Quality Plus Distinction to Blue Cross and Blue Shield of Minnesota for Physician and Hospital Quality Measures 2Health News:Astellas/GlaxoSmithKline's Vesicare Has Advantages Over Pfizer's Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence 2
The Natural Selection family of specialty allografts is spinal concepts response to surgeon requests for spinal allograft devices to eliminate the need for painful autograft harvesting....
Transcranial vascular DWL doppler....
Transcranial vascular DWL doppler....
... Neurocare is a full-featured physiologic testing system offered ... contains many of the features of our flagship ... economical price. , ,The smaller size of the ... environment, the physician's office, a mobile service or ...
Medicine Products: